---
title: "600713.SH (600713.SH) — Related News"
type: "Symbol"
locale: "en"
url: "https://longbridge.com/en/quote/600713.SH/news.md"
symbol: "600713.SH"
name: "600713.SH"
parent: "https://longbridge.com/en/quote/600713.SH.md"
datetime: "2026-05-21T18:49:19.141Z"
locales:
  - [en](https://longbridge.com/en/quote/600713.SH/news.md)
  - [zh-CN](https://longbridge.com/zh-CN/quote/600713.SH/news.md)
  - [zh-HK](https://longbridge.com/zh-HK/quote/600713.SH/news.md)
---

# 600713.SH (600713.SH) — Related News

### [NPGC plans to invest in platform-based R&D companies in the fields of biomaterials and regenerative medicine through a merger and acquisition fund](https://longbridge.com/en/news/287193719.md)
*2026-05-21T09:45:04.000Z*
> NPGC plans to invest no more than 450 million yuan to jointly establish the Daqing M&A Fund with partners, specifically 

### [NPGC: Plans to invest no more than 450 million yuan to jointly establish NPGC Group Daqing Medical Equipment Strong Chain M&A Equity Investment Co., Ltd](https://longbridge.com/en/news/287185567.md)
*2026-05-21T08:47:26.000Z*
> NPGC announced that the company plans to invest no more than 450 million yuan to jointly establish Nanjing Pharmaceutica

### [Others offer a higher price, target company "transfers affection"? NPGC's 120 million yuan investment terminated](https://longbridge.com/en/news/287154209.md)
*2026-05-21T01:37:06.000Z*
> NPGC announced the termination of its investment plan of 120 million yuan in Jiangfeng Biotech, citing that a third part

### [The net profit excluding non-recurring items has declined for three consecutive years, and the demolition compensation cannot hide NPGC's "profit" crisis](https://longbridge.com/en/news/287056765.md)
*2026-05-20T11:23:08.000Z*
> Nanjing Pharmaceutical Group Co., Ltd.'s 2025 annual report shows that although operating revenue increased by 2.36% yea

### [NPGC's acquisition of Jiangfeng Biotech equity "fell through," citing the emergence of another investor](https://longbridge.com/en/news/287109344.md)
*2026-05-20T08:31:06.000Z*
> NPGC announced the termination of its investment in Jiangfeng Biotech due to the discovery that another investor acquire

### [NPC: Net profit of 625 million yuan in 2025, a year-on-year increase of 9.50%](https://longbridge.com/en/news/282331030.md)
*2026-04-10T10:43:31.000Z*
> NPC announced that in 2025, it will achieve an operating income of 54.963 billion yuan, a year-on-year increase of 2.36%

### [NPC: Progress has been made in the investment cooperation with private equity funds](https://longbridge.com/en/news/279910689.md)
*2026-03-20T08:37:46.000Z*
> NPC has made progress in its cooperation with private equity funds for investment matters, planning to invest CNY 120 mi